The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
 
 

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of < or =30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.[1]

References

  1. An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Fiedler, W., Mesters, R., Heuser, M., Ehninger, G., Berdel, W.E., Zirrgiebel, U., Robertson, J.D., Puchalski, T.A., Collins, B., Jürgensmeier, J.M., Serve, H. Leuk. Res. (2010) [Pubmed]
 
WikiGenes - Universities